## **Core Concept**
Non-alcoholic fatty liver disease (NAFLD) encompasses a range of liver conditions affecting people who drink little to no alcohol. It is closely linked to **obesity**, **insulin resistance**, and **dyslipidemia**, with **diabetes mellitus** being a significant risk factor. NAFLD can progress from simple steatosis (non-alcoholic fatty liver, NAFL) to non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis.

## **Why the Correct Answer is Right**
The statement that NAFLD is associated with **transaminitis** (elevations in liver enzymes such as ALT and AST) is accurate. This condition is often discovered incidentally during imaging studies or when abnormal liver enzymes are found on routine blood tests. The connection to **diabetes** (option a) is well-established, as insulin resistance plays a key role in the pathogenesis of NAFLD. NAFLD is also **commonly associated with cryptogenic cirrhosis** (option c), as some patients with cryptogenic cirrhosis may actually have end-stage NAFLD.

## **Why Each Wrong Option is Incorrect**
- **Option B:** Clofibrate is a fibric acid derivative used to lower cholesterol and triglyceride levels. While it may affect liver enzymes, it's not a primary treatment for NAFLD. In fact, fibrates can sometimes increase liver enzymes and are used cautiously in patients with liver disease.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that NAFLD is the **most common liver disorder** in Western industrialized nations and is closely associated with **metabolic syndrome**. The diagnosis of NAFLD often involves ruling out other causes of liver disease, and liver biopsy is the gold standard for distinguishing between simple steatosis and NASH.

## **Correct Answer:** D.